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The Dutch Parelsnoer Institute-Cerebrovascular accident (CVA) Study is part of the Parelsnoer Institute 
(PSI), initiated in 2007 by the Netherlands Federation of University Medical Centers (NFU). PSI is a 
cooperation of all eight Dutch University Medical Centers (UMCs) and aims at building large prospectively 
collected datasets with uniformly and standardized storage of biomaterials for complex diseases. 
Currently, PSI covers 18 disease-specific cohorts called ‘Pearls’, and this number is still growing. One of 
these cohorts is the Stroke or CVA Pearl. For each of the cohorts, PSI offers the UMCs an infrastructure 
and standard procedures for storing the specific biomaterials in their certified biobanks. Clinical data 
are stored in a central database after being pseudonymized to ensure patient privacy. For the Parelsnoer 
Institute-CVA Study, blood for genetic analysis, serum and plasma are collected according to nationally 
agreed standards. Currently (November 2017) the Stroke Pearl has stored blood samples with prospectively 
obtained clinical data of around 6000 patients in all UMCs combined. Blood samples and data are available 
for all researchers with a methodologically valid research proposal.
Keywords: Stroke; harmonized standards; clinical biobanking; translational medical research; health 
 innovation; technical and organizational interoperability; international security and privacy standards
Funding statement: PSI was founded in 2007 with a five year grant from the Dutch Government. From 
2011 until now PSI is funded and facilitated by the Netherlands Federation of University Medical Centers 
(NFU) and its member institutions, independent of external funds. Additional funds from governmental 
sources, industry sponsors and charity are used for the analysis on the existing data and the expansion 
of PSI with new diseases.
(1) Overview
Project description
The Dutch Parelsnoer Institute-Cerebrovascular accident 
(CVA) Study is part of the Parelsnoer Institute (PSI), initi-
ated in 2007 by the Netherlands Federation of University 
Medical Centers (NFU) [1]. PSI is a cooperation of all eight 
Dutch University Medical Centers (UMCs) and aims at 
building large prospectively collected datasets with uni-
form and standardized storage of biomaterials for com-
plex diseases. Currently, PSI covers 18 disease-specific 
cohorts called ‘Pearls’, and this number is still growing 
[2–18]. PSI is centrally organized and has an executive 
board for operational management to ensure collective 
standardization strategies. Additionally, a team of PSI 
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experts supports researchers and the executive boards 
of the participating UMCs with implementing these 
strategies. Standardization between and within UMCs is 
 established via multiple standard operating procedures 
(SOPs) regarding i) storing of biobank materials in the 
certified biobanks of the UMCs. These SOPs are developed 
by biobank coordinators from all UMCs together and 
cover all phases of biobanking. ii) managing the clinical 
 database for every specific disease, hosted via a web based 
application (ProMISe) [1, 19] (Figure 1).
For the Dutch Parelsnoer Institute-CVA Study, each UMC 
stores blood for genetic analysis, serum, and plasma in their 
own certified biobank. The creation of large stroke cohorts 
is currently of great importance in genetic stroke research, 
illustrated by genome-wide association  studies (GWASs) 
performed in the last years [20–23]. Stroke is a heteroge-
neous disease consisting of several  etiological subtypes 
with different underlying pathophysiological mechanisms. 
These subtypes include ischemic stroke and transient 
ischemic attack (TIA), cerebral venous sinus thrombosis, 
intracerebral hemorrhage and subarachnoid hemorrhage. 
Ischemic stroke mainly consists of the subtypes large 
vessel atherosclerosis, cardio-embolism and small vessel 
disease. Large etiological subtypes of intracerebral hemor-
rhage are small vessel disease and vascular malformations. 
Aneurysmal subarachnoid hemorrhage can be classified 
as aneurysmal or perimesencephalic. Most subtypes are 
thought to have a specific genetic  architecture, as GWASs 
have found multiple genetic loci to be subtype-specific. 
Future genetic stroke research may lead to management 
approaches more tailored to the different subtypes and 
novel therapeutical targets [20, 21, 24].
The aim of the Dutch Parelsnoer Institute-CVA Study is 
first to create a large prospective cohort of stroke patients 
with blood samples and DNA collected through stand-
ardized procedures and stored in an uniform way. These 
samples are coupled with stroke subtypes according to 
the TOAST classification and the ASCO system. The Trial 
of Org 10172 Acute Stroke Treatment (TOAST) classifi-
cation distinguishes i) large-artery atherosclerosis, ii) 
 cardio-embolism, iii) small vessel occlusion, iv) stroke of 
other determined etiology and v) stroke of undetermined 
etiology as etiological stroke subtypes [25]. The ASCO 
 system (where A stands for atherosclerosis, S for small 
 vessel disease, C for Cardiac source, O for other cause) clas-
sifies similar subtypes, though both classification schemes 
have been found to have different characteristics in prac-
tice [26, 27]. These classifications enable us to investigate 
associations between genetic risk loci and stroke subtypes 
and to enable pooling with data of other ongoing genetic 
stroke studies [20, 21, 25, 27]. Second, besides genetic 
research the Parelsnoer Institute-CVA Study population is 
Figure 1: Organogram of the Parelsnoer Institute.
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also very well suited for epidemiological studies because 









All eight Dutch University Medical Centers: Academic 
Medical Center (Amsterdam), Erasmus Medical Center 
(Rotterdam), Leiden University Medical Center, Maastricht 
University Medical Center, Radboud University Medical 
Center (Nijmegen), University Medical Center Groningen, 







For the Parelsnoer Institute-CVA Study, the UMCU started 
collecting data in 2009, the seven other UMCs started in 
2010. Data collection is ongoing in five UMCs, no end date 
has been determined. 
Temporal coverage for accessibility
The blood samples are available for researchers with a 
methodological valid research proposal (see access criteria 
for more information); no end date has been determined. 
(2) Methods
Patients
Inclusion criteria for the Dutch Parelsnoer Institute-CVA 
Study are a diagnosis of TIA or stroke, presenting in one 
of the eight Dutch UMCs within one month after stroke 
onset. Stroke encompasses ischemic stroke, cerebral 
venous sinus thrombosis, intracerebral hemorrhage, and 
subarachnoid hemorrhage (both aneurysmal and per-
imesencephalic hemorrhage). Further inclusion criteria 
are age >18 years and the provision of informed consent. 
Informed consent is defined as written consent by the 
donors to collect data and biological samples in a Biobank 
for future scientific purposes in order to study etiopatho-
genesis and the clinical course of CVA. Informed consent 
includes the option for the donors to revoke their con-
sent any time, after which the data and biomaterials will 
be removed from the CVA Biobank, except for the data 
and samples already included in research protocols. These 
very broad inclusion criteria result in the incorporation 
of nearly all stroke patients seen in Dutch UMCs in the 
Dutch Parelsnoer Institute-CVA Study database. For every 
patient, data on medical history, family history, vascu-
lar risk factors, medication use and exact time of stroke 
symptom onset are recorded. Deficits in  neurological 
examination at baseline are recorded according to the 
National Institutes of Health Stroke Scale (NIHSS), a 
graded assessment of consciousness, eye movements, vis-
ual fields, motor and sensory impairments, ataxia, speech, 
cognition and inattention [29]. Ischemic stroke subtype 
is defined according to both the TOAST classification and 
the ASCO system [26, 27]. Data are collected on treatment 
such as intravenous thrombolysis, neurosurgical (clipping 
or decompressive surgery) or endovascular (coiling of 
aneurysms, intraarterial thrombectomy or thrombolysis) 
intervention, start of oral anticoagulation treatment in 
case of atrial fibrillation, and start of secondary prophylac-
tic treatment. Additionally, we collect data on laboratory 
investigations and on imaging, i.e. brain CT and CT angi-
ography, brain MRI and MR angiography and ultrasound 
investigations. After three months functional outcome is 
prospectively recorded via a structured telephone inter-
view, using the modified Rankin Scale [30].
Steps
For the Parelsnoer Institute-CVA Study, a specific Parelsnoer 
Repository for Information Specification, Modelling and 
Architecture (PRISMA) has been defined. PRISMA is an 
information model enabling us to reuse electronic health 
record (EHR) information for scientific purposes. This reuse 
of information minimizes registration burden while at the 
same time routine care procedures are taken into account. 
The architecture is in agreement with national and interna-
tional classifications such as International Classification of 
Diseases and Related Health Problems (ICD-10), SNOMED 
CT and the Logical Observation Identifiers Names and 
Codes (LOINC®) [1]. For all stroke patients included in the 
Parelsnoer Institute-CVA Study, all predefined demographic 
and clinical variables including data on functional outcome 
are recorded as coded data via PRISMA and are sent to the 
central PSI database, a validated web based application 
(ProMISe) [19]. Additionally, blood for genetic analyses, 
serum and plasma are collected, preferably during routine 
clinical procedures. Blood samples are then stored in certi-
fied UMC biobanking facilities adhering to the PSI biobank-
ing protocol. This protocol covers all phases of biobanking, 
from collection to storage of the samples. Metadata on 
blood samples and the unique sample code are registered 
in the central database together with the clinical data. 
Stabilization/preservation
Table 1 gives a summary of procedures on  collection, 
 processing and storage of samples defined in the 
 biobanking protocol of PSI.




Shipping temperature from patient/source to 
preservation or research use
See Table 1.
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Shipping temperature from storage to research use
–80°C (on dry ice).
Quality assurance measures
PSI uses two main strategies to guarantee uniform 
 collection and storage of clinical data between UMCs 
which are i) limiting the number of collected variables to 
only the essentials and ii) using existing EHR infrastruc-
ture within UMCs infrastructure for recording of data. 
As there is no possibility to improve quality of biomate-
rials afterwards, strict adherence to biobank related SOPs 
optimizing integrity of biomaterials is needed. Biobank 
coordinators from all UMCs have together developed 
the PSI biobanking protocol, encompassing all phases of 
biobanking, i.e. sample collection, pre-analysis, registra-
tion, processing and storage. 
The biobanking protocol according to Biospecimen 
Reporting for Improved Study Quality (BRISQ) is as follows 
[31]. Blood collection for the CVA Biobank is performed 
according to the biobank SOP. EDTA blood (10 ml) and 
Serum blood (10 ml) are collected by venipuncture in the 
arm. Collection of smaller tubes and pooling of samples 
is not allowed. Clotting time for serum is defined at 60 
minutes at room temperature. Blood is to be stored at 
room temperature until centrifugation. Centrifugation is 
to be performed at 2000 g either at room temperature 
or at 4°C. Aliquoting is in volumes of 0.5 ml in at least 
5 quantities. Processing time from venipuncture to stor-
age in freezer at –80°C is predefined at preferably 2 hours 
with a maximum of 4 hours. All samples are stored under 
unique identifiers without identifiable patient informa-
tion. DNA samples from EDTA blood are to be processed 
within 4 weeks when stored at 4°C or within 3 months 
when stored at ≤–20°C. Processed DNA should be stored 
as at least 2 stock solution aliquots at ≤4°C with unique 
samples codes, including concentration and quality data 
based on the OD 260/280 ratio. All processing and quality 
data, including specific  time points to assess processing 
time and track and trace of the samples are registered in 
a local Biobank Management Information System. Core 
samples data are provided to the central infrastructure of 
the Parelsnoer Institute CVA Biobank. In addition to the 
processing data deviations from the Biobank SOP per indi-
vidual sample, if applicable, are also registered in the data-
base. These SOP deviations include: hemolytic, lipemic, 
icteric, wrong blood tube, incomplete filling of the blood 
tube, temperature deviation, processing time deviation, 
mixing problems, centrifugation deviation, storage prob-
lems and free text remarks (Table 1).
Source of associated data 
Data are recorded from electronic health records and 
laboratory reports. Each UMC has its own research IT 
infrastructure that delivers the data to their local data-
base in ProMISe, a web based application. The infor-
mation supplied by each UMC is first validated and 
then periodically uploaded to the central Parelsnoer 
Institute-CVA Study database in ProMISe for storage on 
a national level. During uploading, identifying patient 
data are encrypted using special software of a trusted 
third party (Trusted Reversible Encryption Service®, 
Houten, Utrecht, The Netherlands). As additional meas-
ure for protection of privacy, the identifying data are 
encrypted again when exported from the central data-
base for research purposes. In specific situations, e.g. 
in case of incidental findings that need feedback to the 
patient or in case of data-linkage, de-pseudonymization 
can be performed by authorized personnel. The PSI IT 
infrastructure is in agreement with privacy and interna-
tional security standards [1].
Ethics Statement
The Parelsnoer Institute-CVA Study Group uses a 
patient information brochure, regulations and a con-
sent form, approved by the local Medical Ethical 
Committees (MECs) of all UMCs. Subsequently, both 
MECs and Board of Directors of the remaining par-
ticipating UMCs approved local implementation of 
the biobanking activities [1]. The study is performed 
according to the principles of the Declaration of 
Helsinki and in accordance with the Medical Research 
Involving Human Subjects Act and codes on ‘good use’ 
of clinical data and biological samples as developed by 
the Dutch Federation of Medical Scientific Societies 




Processing Time Aliquoting Storage Additional 
information
Serum 10 ml clotted 
blood
2000 × g at room 
temperature or 4°C 
for 10 minutes
Within 2–4 hours ≥5 × 0.5 ml –80°C SOP deviations*
EDTA plasma 10 ml 2000 × g at room 
temperature or 4°C 
for 10 minutes
Within 2–4 hours ≥5 × 0.5 ml –80°C SOP deviations*
DNA (blood) 10 ml EDTA 
blood
Whole blood or 
cell pellet, to UMC 
specifications
Within 4 weeks (4°C) 





OD ratio 260/280, 
 concentration in μg/ml*
* See the ‘Quality assurance measures’ section for detailed additional information.
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[32, 33]. All patients should give written informed 
 consent prior to inclusion. 
Constraints
Only patients who have provided written informed con-
sent are included. The PSI does not include healthy 
 controls. After inclusion, patients may withdraw their 
consent at any time. The patient can express the wish 
to withdraw to his/her doctor, in which case the doctor 
will ensure that data and materials are destroyed unless 
needed for validation of earlier issuance.
(3) Bioresource description
Object name
The Parelsnoer Institute-CVA Study 
Bioresource name 
The Parelsnoer Institute-CVA Study 
Bioresource location
All eight University Medical Centers across the Netherlands 
participate in PSI:
1. Academic Medical Center
 Meibergdreef 9
 1105 AZ Amsterdam 
 The Netherlands
2. Erasmus Medical Center
 ’s-Gravendijkwal 230
 3015 CE Rotterdam
 The Netherlands
3. Leiden University Medical Center
 Albinusdreef 2
 2333 ZA Leiden
 The Netherlands
4. Maastricht University Medical Center
 P. Debyelaan 25
 6229 HX Maastricht
 The Netherlands
5. Radboud University Medical Center
 Geert Grooteplein-Zuid 10
 6525 GA Nijmegen
 The Netherlands
6. University Medical Center Groningen
 Hanzeplein 1
 9713 GZ Groningen
 The Netherlands
7. University Medical Center Utrecht
 Heidelberglaan 100
 3584 CX Utrecht
 The Netherlands
8. VU University Medical Center
 De Boelelaan 1117














For the Dutch Parelsnoer Institute-CVA Study blood for 
genetic analysis, serum and plasma are collected and 
stored (Table 1).
Type of sampling
The Dutch Parelsnoer Institute-CVA Study is a disease 
based cohort with longitudinal collections, sampled in 
clinical care.
Anatomical site 
The brain and cerebral vasculature, including cervical 
vessels.
Clinical characteristics of patients/source
For the Dutch Parelsnoer Institute-CVA Study, a full clinical 
characterization, including extensive diagnostics, demo-
graphics, therapeutics and clinical follow-up is specified.
Vital state of patients/source
All patients are alive at inclusion.
Clinical diagnosis of patients/source
Ischemic stroke and transient ischemic attack (TIA), 
 cerebral venous sinus thrombosis, intracerebral 
 hemorrhage, and subarachnoid hemorrhage (both 




The Parelsnoer Institute does not collect control samples 
from healthy individuals. 
Biospecimen type 
For the Dutch Parelsnoer Institute-CVA Study blood sam-
ples for genetic analysis, serum and plasma are collected 
and stored. Table 1 gives a summary of procedures on 
 collection, processing and storage of samples defined in 
the biobanking protocol of PSI.
Size of the bioresource 
As of November 3rd 2017, clinical data of 6074 and blood 
samples of 5769 patients were available in the Dutch 
Parelsnoer Institute-CVA Study. Of all patients with 
clinical data, 4390 had a final diagnosis of ischemic 
stroke (72%), 786 of subarachnoid hemorrhage (13%), 
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599 of intracerebral hemorrhage (10%), 114 of cerebral 
venous sinus thrombosis (2%). Further, 48 patients 
(1%) had another final stroke diagnosis and of 137 
patients (2%) final diagnosis was missing. PSI has no 
end date. 
Release date
Data and samples of the Dutch Parelsnoer Institute-
CVA Study are currently available. Regarding all disease 
cohorts, the research projects based on PSI data and sam-
ples have led to several scientific publications [2–16, 18].
Access criteria
PSI has an online open access catalogue with up-to-date 
information about the content of the Dutch Parelsnoer 
Institute-CVA Study, providing insight for research-
ers worldwide and offering them the opportunity to 
submit a research proposal to the Dutch Parelsnoer 
Institute-CVA Study and request its data and blood sam-
ples [17]. These proposals are reviewed by the scien-
tific committee of the Dutch Parelsnoer Institute-CVA 
Study, consisting of representatives of the Pearl and 
independent scientific experts. This committee judges 
whether the proposed study is relevant, methodologi-
cally valid, compliant with the scientific aims of the 
Dutch Parelsnoer Institute-CVA Study Group and with 
the privacy protection rules. In addition to this scien-
tific committee, the Research Ethical Committee of the 
coordinating UMC and several other participating cent-
ers have to grant permission according to local policy. 
When the proposal is accepted by all committees, data 
from the central PSI facilities will be delivered by the 
PSI data manager to the researcher. Requested bioma-
terials will be delivered by the biobank coordinators of 
the UMCs. If the subsequent research project results in 
new individual data on the biosamples, PSI demands 
these newly acquired data to be made publicly available 
for future research purposes. For researchers using PSI 
data, costs are involved. These costs include direct costs 
for retrieval of the samples from the UMC biobanks and 
shipment of the samples. In addition, depending on the 
defined collaboration with external researchers, consor-
tia or industrial partners additional costs will be negoti-
ated for the Biobank related acquisition costs, sample 
and data collection, research project costs and contri-
bution to the sustainability of the Parelsnoer Institute 
CVA-Biobank. 
(4) Reuse potential
Samples from the same donor may be used for multiple 
projects. The researcher may only receive samples and 
data on two conditions: i) they share their scientific find-
ings with PSI and provide PSI with a copy of the published 
paper, and ii) they acknowledge the Dutch Parelsnoer 
Institute-CVA Study Group in all publications of studies 
using PSI data and samples. 
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